eamag/protocols-with-steps huggingface dataset:
TITLE: Automated Blood Pressure (Oscillometric Technique)
AUTHORS: insightsmovement

[DESCRIPTION]
The following SOPs outline how to take a blood pressure measurement using an automated device.

Blood-pressure measurement is warranted in any situation that requires assessment of cardiovascular health, including screening for hypertension and monitoring the effectiveness of treatment in patients with hypertension.

[STEPS]
SECTION: Equipment Required
1. Validated Oscillometric Device

 

SECTION: Preparing for the Measurement
2. Follow the Steps below to help prepare your PPC for measurement:

The patient’s back and legs should be supported with legs uncrossed and feet resting on a firm surface

The patient’s arms should be bare to the shoulder the arm should be supported at heart level.

The appropriate cuff should be selected by measuring the arm circumference at the midpoint of the upper arm which is the half way point between the acromion and the olecranon processes.

After choosing the correct cuff based upon the sizing, it should be wrapped around the arm approximately 2cm above the crease of the elbow, with the mid line of the cuff placed directly over the brachial artery.

The cuff should be tight, but you should still be able to fit two fingers underneath the bottom of the cuff. 
SECTION: Blood Pressure Measurement
3. 1. Ensure you are familiar with the guidelines from the manufacturer of how to use the blood pressure device.

2. Use the appropriate button or function to start the blood pressure measurement.

3. Blood pressure should be taken twice, with at least one-minute in-between measurements.

4. This should be conducted without talking to the individual in-between measurements
SECTION: Considerations
4. Blood pressure should be taken in a quiet room.

Blood pressure should not be taken if the individual has recently engaged within physical activity, used tobacco, ingested caffeine or eating within the last 30 minutes.
SECTION: Interpretation
5. Blood pressure readings can be categorised by the following criteria (ACSM):

     Category      Systolic.mmHg.      Diastolic.mmHg.        Normal      <120      <80        Prehypertension      120-139      80-89        Stage 1   Hypertension      140-159      90-99        Stage 2 Hypertension      >160      >100
TITLE: No Title
AUTHORS: 

[DESCRIPTION]
<div>
<div>
<div>
<div class="b-start-block editable-content">
<p>This protocol describes MRI and ADHD Quotient Test for Session 8 of the following work:</p>
<p> </p>
<p>David O'Connor, et. al. (2017) The Healthy Brain Network Serial Scanning Initiative. <em>GigaScience...</em></p>
</div>
</div>
</div>
</div>

[BEFORE_START]
<p>Participant offered use of restroom, preganancy test administered to female participants if they are of childbearing age, and consent is acquired</p>

[STEPS]
?. 
?. 
?. 
?. 
?. 
?. 
?. 
?.
TITLE: a protein precipitation extraction method
AUTHORS: Idha Arfianti

[STEPS]
?. The frozen plasma was thawed at room temperature (25 ± 1°C).
?. The thawed plasma was vortexed to ensure the sample was homogenous.
?. To each 100 µL plasma sample, 50 µL of internal standard (IS) (containing 2 µg/mL of IS) was added, followed by the addition of 250 µL of acetonitrile (ACN).
?. The mixture was vortexed, shaken for 5 s, and centrifuged for 2 min at 14800 rpm.
?. The supernatant was filtered with a 0.2 µm syringe filter, then transferred to new a vial.
?. Two microliters were then injected into the LC-MS/MS system.
TITLE: No Title
AUTHORS: 

[DESCRIPTION]
<p>Please contact Dr. Steven Wilhelm (wilhelm@utk.edu) for additional information regarding this protocol</p>
<p> </p>
<p>Modified from Pardee, A. B., F. Jacob, and J. Monod. 1959. The genetic control and cytoplasmic expression of "inducibility" in the synthesis of ß-galactosidase in E. coli. J. Mol. Biol. 1:165-178</p>

[STEPS]
?. 
?. 
?. 
?. 
?.
TITLE: Purification of RNA from the Aqueous Phase Following TRIzol®/Chloroform Extraction using the Monarch® RNA Cleanup Kits
AUTHORS: New England  Biolabs

[DESCRIPTION]
<div class = "text-blocks"><div class = "text-block"><span>RNA isolation reagents containing guanidine thiocyanate and phenol (e.g., TRIzol, RNAzol®, QIAzol®, etc) combined with chloroform extraction, are often used for sample lysis and RNA purification. The aqueous phase from any guanidinium thiocyanate-phenol-chloroform extraction can be cleaned up using the Monarch RNA Cleanup Kits (</span><a href="https://international.neb.com/products/t2030-monarch-rna-cleanup-kit-10-ug" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;">NEB #T2030</span></a><span>, </span><a href="https://international.neb.com/products/t2040-monarch-rna-cleanup-kit-50-ug" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;">T2040</span></a><span>, </span><a href="https://international.neb.com/products/t2050-monarch-rna-cleanup-kit-500-ug" style = "text-decoration:underline;color:blue;cursor:pointer;"><span style = ":;">T2050</span></a><span>), thereby eliminating the need for tedious RNA precipitation step</span></div></div>

[STEPS]
?. Re-insert the column into the collection tube. Add  RNA Cleanup Wash Buffer and spin for . Discard the flow-through.
500 µl
To save time, spin for 30 seconds, instead of 1 minute.
?. Following guanidinium-thiocyanate-phenol-chloroform extraction, carefully transfer the upper aqueous phase into an RNase-free tube (not provided).
?. Add 1 volume of ethanol (≥ 95 %).
?. Insert an RNA cleanup column into a collection tube, load sample onto the column and close the cap.
?. Repeat wash (Step 6).
?. Transfer the column to an RNase-free 1.5 ml microfuge tube (not provided). Use care to ensure that the tip of the column does not come into contact with the flow-through. If in doubt, re-spin for 1 minute to ensure traces of salt and ethanol are not carried over to next step.
?. Elute in nuclease-free water according to the table below. The eluted RNA can be used immediately or stored at .   ABCD1KITELUTION VOLUMEINCUBATION TIMESPIN TIME2T20306 – 20 µlN/A1 minute3T204020 – 100 µlN/A1 minute4T2050**50 – 100 µl5 minutes (Room temp.)1 minute
-70 °C
Care should be used to ensure the elution buffer is delivered onto the center of the matrix and not the wall of the column to maximize elution efficiency.
ABCD1KITELUTION VOLUMEINCUBATION TIMESPIN TIME2T20306 – 20 µlN/A1 minute3T204020 – 100 µlN/A1 minute4T2050**50 – 100 µl5 minutes (Room temp.)1 minute
To save time, spin for 30 seconds, instead of 1 minute.
?. Mix well by pipetting up and down or flicking the tube. Do not vortex.
?. Spin for , then discard flow-through. For diluted samples ≥ 900 μl, load a portion of the sample, spin, and then repeat as necessary.
To save time, spin for 30 seconds, instead of 1 minute.
TITLE: pGEM-T连接
AUTHORS: 张 雪

[STEPS]
?. AB12× ligation buffer（用前振荡混匀）5µl2PCR回收产物3µl3pGEM-T Vector1µl4T4 ligase1µl
on ice
AB12× ligation buffer（用前振荡混匀）5µl2PCR回收产物3µl3pGEM-T Vector1µl4T4 ligase1µl
?. 室温1h（20°C左右，16°C最佳）
16 °C
?. 随后4°C过夜
4 °C
TITLE: Chapter 10: Medications
AUTHORS: Kerri Wolter

[DESCRIPTION]
<div class = "text-blocks"><div class = "text-block">This protocol provides information about medications for vulture rehabilitation and how to calculate drug dosage.</div></div>

[STEPS]
?. [How to calculate volume of the drug]
Calculate the dose required by multiplying the required dose rate (mg/kg) by the bird’s weight (kg). This gives you the dose required in mg.
?. [How to calculate volume of the drug]
To calculate the volume of drug required, you need to divide this value by the drug concentration (mg/ml).
For example:
 Drug dosage 20 mg/kg     Bird weight 10 kg     Concentration 50 mg/mL 
20 x 10 = 200 mg. This is the dose of drug a 10k g bird must receive. 200 / 50 = 4ml. This is the volume of drug to be administered.
TITLE: RNAi imaging
AUTHORS: Ben Jenkins

[DESCRIPTION]
Imaging of P. bursaria cultures

[STEPS]
SECTION: Preparing plates
1. In a sterile hood, resuspend plate using a multichannel pipette.

#Ensure pipettes do not overlap with multiple Wells
#Pipette up and down ~20 times (10x in the middle, 10x moving clockwise around the edge)
SECTION: Preparing plates
2. Spin plate at 800 x g, 5 min, 4 °C 

# 800* (*=xg)
# Ensure rad is set to 16.3 
# Ensure that centrifuge is loaded with balance plate 
SECTION: Imaging plates
3. Transfer plate to the HC screener, aligned to the left hand corner. 
SECTION: Imaging plates
4. Run protocol "Paramecium_RNAi_A" (this takes ~10 min)

Name: rnai_[experiment name]_plate[*]A_t[*]_[date]
Select storage: Ben_2 

# [*] corresponds to the specific plate number, and day, respectively

SECTION: Imaging plates
5. Repeat Step 2, and transfer plate back to the HC screener.

Run protocol "Paramecium_RNAi_B" (this takes ~10 min)

Name: rnai_[experiment name]_plate[*]B_t[*]_[date]
Select storage: Ben_2 

# [*] corresponds to the specific plate number, and day, respectively
# Running both protocols A and B will collectively image the entire plate, these are run seperately so that cells do not have time to move from the bottom of the well for imaging
SECTION: Imaging plates
6. Return plate to 23 °C culture room.
TITLE: No Title
AUTHORS: 

[GUIDELINES]
<strong>Primers:</strong><br /><br />attP_F502:&nbsp; CTC CTC AAC TGC CAG GAC TC&nbsp;&nbsp;&nbsp;&nbsp; (PSS2 target 502bp upstream of att: 90315-90334)<br />attP_R141:&nbsp; CCC AACAAG CTC TCA GGA AG&nbsp;&nbsp;&nbsp; (PSS2 target 141bp downstream of att rev: 91010-91029)<br /><br /><strong>Reaction Mix</strong><br /><br />
<table>
<tbody>
<tr>
<td>Reagent</td>
<td>Amt.</td>
<td>Final Conc.</td>
</tr>
<tr>
<td>Water</td>
<td>18.25&mu;l</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>10x Buffer (no Mg)</td>
<td>2.5&mu;l</td>
<td>=1x</td>
</tr>
<tr>
<td>25mM MgCl<sub>2</sub></td>
<td>1.5&mu;l</td>
<td>=1.5mM</td>
</tr>
<tr>
<td>dNTP mix, 10mM each</td>
<td>0.5&mu;l</td>
<td>=200&mu;M ea.</td>
</tr>
<tr>
<td>Primer F502, 10&mu;m</td>
<td>0.5&mu;l</td>
<td>=0.2&mu;M</td>
</tr>
<tr>
<td>Primer R141, 10mM</td>
<td>0.5&mu;l</td>
<td>=0.2&mu;M</td>
</tr>
<tr>
<td>Sigma Taq 5U/&mu;l</td>
<td>0.25&mu;l</td>
<td>=0.05U/&mu;l</td>
</tr>
<tr>
<td>DNA (viral lysates)</td>
<td>1.0&mu;l</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Total</td>
<td>25&mu;l</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<br /><br /><strong>Cycling</strong><br /><br />
<table>
<tbody>
<tr>
<td>95&deg;C</td>
<td>3 min</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>95&deg;C</td>
<td>15sec</td>
<td rowspan="3"><br />35 cycles<br /><br /></td>
</tr>
<tr>
<td>60&deg;C</td>
<td>30sec</td>
</tr>
<tr>
<td>72&deg;C</td>
<td>30sec</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>72&deg;C</td>
<td>10min</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>15&deg;C</td>
<td>Hold</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<br /><br /><br />

[STEPS]
TITLE: HPLC sample prep
AUTHORS: Kaitly Woodard

[DESCRIPTION]
<div class = "text-blocks"><div class = "text-block">Preparation of blood for hemoglobin separation (ion-exchange and reverse-phase HPLC).</div></div>

[STEPS]
?. Prepare 1.5mL Eppendorf tubes with 200uL of Hemolysate Reagent
?. Add 1uL of blood to tube, and vortex for 5 seconds.
?. Centrifuge at max speed for 10 minutes
?. Pipette out 75-100uL of supernatant into HPLC vial, careful not to disturb DNA pellet at the bottom of the tube. If pipette tip appears sticky after removal from supernatant you may have taken the DNA. Instead, disgard the sticky debris and pipette from remainder of supernatant. (The DNA and cell debris will stay together, once it is removed only desired hemolysate will remain).
?. Ensure vial is labeled appropriately, and no bubbles are present at the bottom of the vial. Bubbles can be removed by tapping the vial gently on the benchtop or removing by pipette.
?. **Reserve HPLC time on the calendar, provide sample list and samples to JJZ
TITLE: Hematoxyllin-Eosin ( HE ) Staining
AUTHORS: Freda Halim

[DESCRIPTION]
This is a protocol to stain tissue with Hematoxyllin-Eosin ( HE ) Staining. We use human breast cancer tissue for running this protocol.

[STEPS]
SECTION: Deparaffinization
1. Incubate slides in Xylol
SECTION: Deparaffinization
2. Incubate slides in Xylol
SECTION: Rehydration
3. Incubate slides in 100% Alcohol
SECTION: Rehydration
4. Incubate slides in  96% Alcohol
SECTION: Rehydration
5. Incubate slides in 80% Alcohol
SECTION: Rehydration
6. Incubate Slides in  70% Alcohol
SECTION: Rehydration
7. Rinse slides with Aquadest for 5 minutes
SECTION: Nuclear Staining
8. Incubate Slides in  Hematoxyllin Reagent  ( Hematoxyllin JT Baker ) 
SECTION: Nuclear Staining
9. Rinse slides with running tap water
SECTION: Defferentiation
10. Incubate slides in bluing reagent @ 1 minutes, 5 times
SECTION: Defferentiation
11. Rinse slides with running tap water 
SECTION: Cytoplasm staining
12. Incubate slides in Eosin reagent 1 minute
SECTION: Dehydration
13. Incubate Slides in 70% Alcohol
SECTION: Dehydration
14. Incubate Slides in 80% Alcohol
SECTION: Dehydration
15. Incubate Slides in 96% Alcohol
SECTION: Dehydration
16. Incubate Slides in 100% Alcohol
SECTION: Clearing
17. Incubate Slides in Xylol
SECTION: Clearing
18. Incubate slides in Xylol
SECTION: Clearing
19. Incubate Slides in Xylol
SECTION: Mounting and Finishing
20. Wipe excess fluid,cover the slides with cover glass
TITLE: Testowy protokół
AUTHORS: lukasz.lukjaniuk  

[DESCRIPTION]
To testowa protokół do zrobienia czegos

[STEPS]
SECTION: Section 1
1. ANB
SECTION: Section 1
2. AScdascd
SECTION: Section 1
3. 
SECTION: Section 1
3.1. 
SECTION: Section 1
3.2. 
SECTION: Section 1
2.1. 
4.
TITLE: Harvesting and irradiation of mouse embryonic fibroblasts (MEFs) for hPSC cultures
AUTHORS: Hanqin  Li, Oriol Busquets, Steven Poser, Dirk Hockemeyer, Frank Soldner

[DESCRIPTION]
This protocol describes the process of harvesting and irradiating mouse embryonic fibroblasts (MEFs) to use as feeder cells for human pluripotent stem cell (hPSC) culture.


General notes
1. Throughout this protocol, the term hPSC is used to collectively refer to both hiPSCs and hESCs. All described procedures have been tested and work equally well for hiPSCs and hESCs.
2. MEFs were obtained as described in Manipulating the Mouse Embryo: A Laboratory Manual, Third Edition (ISBN: 0879695919)
 




[STEPS]
1. Wash the plates once with 10 ml DPBS for each 15-cm plate.
2. Add 3 ml Trypsin and incubate for in 37°C; 5% CO2 for 10 min 

3. Add 9 ml MEF medium to neutralize the Trypsin. Collect cell suspension in a 50 ml conical tube.
4. Rinse the plate with 9 ml of new MEF medium to collect the remaining cells.
5. If there are cell clumps that not fully dissociated, let the clumps settle by gravity for 3 min then transfer the single cell suspension to a new conical tube. Cells in clumps are usually not uniformly irradiated and that may lead to proliferating feeders.
6. Parafilm the conical tubes and bring cells to irradiation.
7. Irradiate the cells in conical tubes at 3500 cGy on Precision X-RAD 320 irradiator.
3.1. MEF medium
TITLE: 16S Arc  109F-934R
AUTHORS: Eva Petrova, Roey Angel

[DESCRIPTION]
Amplification of the marker gene 16S rRNA for general Archaea using primers 109F-934R.
 
109F  or           ACK GCT CAG TAA CAC GT   (target seq. 109 – 125) Grosskopf  et al. (1998),
109F-mod      AHD GCT CAG TAA CAC RT    (target seq. 109 – 125) Miyashita et al. (2009)
934R                GTG CTC CCC CGC CAA TTC CT    (target seq. 915 – 934) Grosskopf  et al. (1998)
 
Expected fragment size: 791bp

[STEPS]
SECTION: PCR mixture
1.  
 
SECTION: PCR program
2. 1.  94◦C – 4′
2.  x 28 - 32 {
       a.  52◦C – 30′′
       b.  72◦C – 45′′
       c.  94◦C – 30′′
      }
3.  52◦C – 30′′
4.  72◦C – 10'
TITLE: ADR Assessment of TB Patients IIPHG
AUTHORS: Harsh Shah, Sandul Yasobant, Jay Patel, Priya Bhavsar, Deepak Saxena, Somen Saha, Anish Sinha [ Department of Public Health Science

[DESCRIPTION]
Tuberculosis (TB) is the second leading cause of death due to infectious diseases globally, and delay in TB care cascade is reported as one of the major challenges in achieving the goals of the TB control programs. The main aim of this study was to investigate the delay and responsible factors for the delay in the various phases of care cascade among TB patients in two Indian states, Jharkhand and Gujarat. This cross-sectional study was conducted among the 990 TB patients from the selected TUs of two states. This study adopted a mixed-method approach for the data collection. The study targeted a diverse profile of TB patients, such as drug-sensitive TB (DSTB), drug resistance TB (DRTB), pediatric TB, and extra-pulmonary TB. It included both public and private sector patients. The study's findings suggested that 172 (29%) patients experienced ADRs with at least one symptom. Out of those, 80% had mild symptoms, and 133 (77%) experienced them during the early (intensive) phase of the treatment initiation. The 18 (56%) drug-resistant TB patients on second-line ATTs reported ADR, 50% of whom reported moderate and severe ADRs. The association between ADR experience and drug susceptibility was significant (p value of 0.005; Chi-squared 12.193) and drug-resistant TB patients experience two times more ADRs than drug-sensitive TB patients (odds ratio 2.049, CI: 1.47–2.86). The TB patients had experienced gastric disturbances, skin-related symptoms, peripheral nervous system symptoms, arthralgia, ophthalmic discomfort, and psychological disorders during ATT. The regression model showed that the Nagelkerke R2 value was 0.139 with a classification accuracy of 71%. The present study focused on adverse events pertaining to TB patients missed by the health system. The analysis delivered crucial conclusions that could direct policymakers to educate and train all healthcare professionals and high-risk patients on how to solicit and manage ADRs among patients receiving programmatic treatment effectively. It is crucial to strengthen the program by carefully examining treatment plans based on medical history, ensuring treatment compliance, managing adverse events aggressively and proactively, and establishing a training cascade for health care providers and treatment supporters.

[STEPS]
TITLE: Magnitude of job satisfaction and intention to leave their present job among nurses in selected Federal Hospitals in Addis Ababa, Ethiopia
AUTHORS: Aynye Woldekiros   Negese*,   Elsabet Getye2, ziyadahm  

[DESCRIPTION]
Background 

Job dissatisfaction issues and Health workers’ intention to leave is an increasing problem that threatens the function of the health care sector worldwide, especially in developing countries, including Ethiopia. As part of future evidence, this study was intended to assess nurses’ job satisfaction and intention to leave their current work and its associated factors in federal public hospitals in Addis Ababa, Ethiopia. 
Method

An institutional-based cross-sectional study design was used to conduct the study. A simple random sampling technique was employed to select 408 nurses from selected federal Hospitals in Ethiopia, and used self-administered questioner to collect the data. Logistic regression was employed to identify the predictor variables with consideration of a statistical significance of P <0.05 adjusted odds ratios calculated at 95% CIs.
Result

The magnitudes of job satisfaction and intention to leave current job among nurses in this study were 47.7% and 80.6%, respectively. Salary is imbalance with demands [AOR=2.85 (1.24, 6.57)], managers who have no a personal plan for developing skills [AOR=3.74 (1.58, 8.87)], stressful jobs [AOR=0.28 (0.11, 0.71)],health problem is a reason for having thoughts about changing jobs [AOR=3.02 (1.17, 7.79)] and a lack of development [AOR=4.13 (1.51, 11.3)]were identified determinant factors for intention to leave.
Conclusion

The overall intention to leave current job among nurses working in selected federal Hospitals in Ethiopia was high. The government of Ethiopia should balance salary of the nurses with the current market level. The hospitals leaders should plan the way nurses develop their educational and job carrier level. 
Key words: Job satisfaction, Intention to leave, turnover, nurses, hospitals, Addis Ababa

[STEPS]
TITLE: Marchantia protoplast
AUTHORS: Eftychis Frangedakis

[STEPS]
?. Grow gemmae on ½ Gamborg B5 plus vitamins media plates (the plates should be covered like Fig. 1A) for 4 days (Fig. 1B).
?. Add 10 ml of 8% (w/v) mannitol at pH 5.7 on the plate and incubate at room temperature 30min.
?. Prepare 2% Driselase solution: add 0.2 g Driselase in 10 ml 8% mannitol solution and incubate in dark for 20 min at RT. Gently invert to mix at intervals. Spin at 3.3k for 3 min. Filter sterilize supernatant using a 0.2 μm filter attached to a syringe.
?. Replace mannitol solution with 5 ml 2% Driselase and incubate at RT for 4 hours with gentle shaking (50 rpm).
?. Using a tip gently release protoblasts from gemmae (Fig.1C).
?. Filter the solution through a 70 μm cell strainer into a 50 ml falcon tube and then transfer in a round bottom falcon tube (Fig. 1D).
?. Incubate for further 10 min.
?. Spin at 120 x g for 3min. Remove thesupernatant without disturbing the cells.
?. Wash the cells by re-suspending themin 6ml 8% mannitol (Mix by swirling not shaking) and spin at 120 x g for 3 min. Repeat the wash 2 times.
?. Add 300 μl 50% glucose in the autoclaved liquid Gamborg B5 plus vitamins + mannitol solution
?.
TITLE: U Michigan - Sirius Red staining
AUTHORS: Jeff Hodgin

[DESCRIPTION]
<div class = "text-blocks"><div class = "text-block"><span style = "font-weight:bold;">Summary: </span></div><div class = "text-block">Picrosirius red staining (also called Sirius red staining) highlights fibrosis by staining collagen (collagen 1 and III fibers) fibers in paraffin-embedded kidney tissue sections. Sirius red stained collagen appears red by light microscopy. When polarized, the birefringence is highly specific for collagen. The larger collagen fibers are bright yellow or orange, and the thinner ones, including reticular fibers, are green.</div></div>

[STEPS]
?. Wash 2x for 5 min in Xylene
?. Wash 2x for 3 min in 100% EtOH
?. Wash 1x for 2 min in 95% EtOH
?. Wash 1x for 2 min in 80% EtOH
?. Wash 1x for 1 min in 70% EtOH
?. Wash in running tap water for 3 min
?. Incubate in hematoxylin for 8 min.
?. Wash in running tap water for 10 min
?. Incubate for 60 min in Picrosirius red solution (do not shorten this time)
?. Wash 2x for 5 min in acidified H²O (Change after each wash)
?. Wash 1x for 1 min in 70% EtOH
?. Wash 1x for 1 min in 80% EtOH
?. Wash 1x for 1 min in 95% EtOH
?. Wash 1x for 1 min in 100% EtOH
?. Wash 2x for 3 min in Xylene
?. Mount slides with mounting medium - 1 drop
?. Insert cover glass carefully, avoid bubble
TITLE: LA Urban Coyote Project Volunteer Training Protocol
AUTHORS: Justin L Brown, Binta Wold, Rachel N Larson

[DESCRIPTION]
<div class = "text-blocks"><div class = "text-block">This scat survey protocol has been developed for use by National Park Service staff of the Santa Monica Mountains National Recreation Area to facilitate the training of citizen science volunteers to collect and analyze coyote scat for the Los Angeles Urban Coyote Project. This protocol provides instructions for the scat project managers to supervise volunteers and train them on how to:</div><div class = "text-block"><ul style = "list-style-type:disc;"><li style = "counter-reset:ol0;list-style-type:disc;">Walk a scat transect and collect scat</li><li style = "counter-reset:ol0;list-style-type:disc;">Identify coyote scat in the field</li><li style = "counter-reset:ol0;list-style-type:disc;">Dissect scat</li><li style = "counter-reset:ol0;list-style-type:disc;">Identify major prey items</li></ul></div><div class = "text-block">In addition, sections of this protocol detail actions carried out by NPS staff, such as volunteer supervision and quality control, and the protocol for sterilizing and washing scats. We hope this protocol is an effective tool for others who are interested in starting a citizen science scat collection/dissection project in their own research.</div></div>

[STEPS]
?.